Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$141.72 - $219.34
Next Earnings Date
May 06 2025
Next Earnings Date
May 06 2025
Latest price
Market Cap | $4.79B |
EV | $4.05B |
Shares Outstanding | 29.93M |
Beta | 0.75 |
Analyst Rating | BUY |
Analyst Target Price | $215.20 |
P/E 2025E | 24.51x |
P/Revenue 2025E | 10.56x |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | 41.10% |
EPS | 65.50% |
Operating Cash Flow | - |
Free Cash Flow | 45.30% |
Gross Margin 2025E | 94.50% |
Net Profit Margin 2025E | 45.59% |
ROE 2025E | 21.21% |
ROCE 2024 | 10.34% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Krystal Biotech, Inc.
KRYS
Sector
Healthcare
Industry
Biotechnology
CEO
Krishnan, Krish
Employees
275
Website
www.krystalbio.comIPO Date
2017-09-20
Headquarters
2100 Wharton Street, Suite 701, Pittsburgh, Pennsylvania, 15203, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved